View email in your browser

Caladrius to Present at Multiple Upcoming
March Conferences

BASKING RIDGE, N.J., Mar. 17, 2016 - Caladrius Biosciences, Inc. (NASDAQ: CLBS) (“Caladrius”), a cell therapy company combining an industry-leading development and manufacturing services provider (“PCT”) with a therapeutic development pipeline, announces today that the Company's management, as well as key opinion leader Atsuhiko Kawamoto, MD, PhD, will present at multiple upcoming March conferences.

14th Congress of the Japanese Society for Regenerative Medicine (JSRM)
  • Date and Time: Saturday, March 19, 2016, 3 PM JST
  • Website:
  • Venue: Osaka International Convention Center, Osaka, Japan
  • Presenter: Dr. Atsuhiko Kawamoto
  • Topic: G-CSF mobilized CD34+ cell therapy for chronic lower limb ischemia
80th Annual Scientific Meeting of the Japanese Circulation Society (JCS)
  • Date and Time: Sunday, March 20, 2016, 4:30 PM JST
  • Website:
  • Venue: Sendai International Center, Sendai, Japan
  • Presenter: Dr. Atsuhiko Kawamoto
  • Topic: An Update on Therapeutic Strategies for Japanese Patients with Critical Limb Ischemia
ARM’s 4th Annual Cell & Gene Investor Day
  • Date and Time: Tuesday, March 22, 2016, 8:50 AM ET
  • Website:
  • Venue: Metropolitan Club, New York, New York
  • Panelist: Dr. Robert Preti, Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer, Caladrius; President of PCT
  • Topic: Cell Therapy Infrastructure & Manufacturing Requirements for Commercialization
BIO Korea 2016 Session 1
  • Date and Time: Thursday, March 31, 2016, 9:20 AM KST
  • Speaker: Dr. Robert Preti, Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer, Caladrius; President of PCT
  • Topic: Recent Trends in Technology Development and Products Commercialization
Session 2
  • Date and Time: Thursday, March 31, 2016, 10:50 AM KST
  • Panelist: Dr. Robert Preti, Senior Vice President, Manufacturing and Technical Operations and Chief Technology Officer, Caladrius; President of PCT
  • Topic: Future Perspectives of Stem Cells and Regenerative Medicine Industry
Sidoti Emerging Growth Convention
  • Date and Time: Thursday, March 31, 2016, 2:30 PM ET
  • Website:
  • Venue: Marriott Marquis Times Square, New York, New York
  • Presenter: Dr. David Mazzo, Chief Executive Officer, Caladrius
  • Topic: Company Presentation
Dr. Kawamoto is the Director of the Unit of Regenerative Medicine and Leader of the Vascular Regeneration Research Group at the Institute of Biomedical Research and Innovation. He is the Vice Director of the Translational Research Informatics Center and Director of the Division of Strategic Development for Clinical Programs at the Foundation for Biomedical Research and Innovation. Dr. Kawamoto will serve as the lead principal investigator for a proposed Phase 2 trial in Japan for CLBS12, the Company’s CD34 cell therapy product candidate for critical limb ischemia.

About Caladrius Biosciences
Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry.  PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi Chemical Co. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. Around the core expertise of PCT, Caladrius strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation. For more information, visit

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the potential for a Phase 2 trial in Japan for CLBS12. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the SEC, including: risks related to:  (i) our expected continued losses and negative cash flows; (ii) our anticipated need for substantial additional financing; (iii) the significant costs and management resources required to comply with the requirements of being a public company;  (iv) the possibility that a significant market for cell therapy may not emerge; (v) the potential variability in PCT’s revenues; (vi) PCT’s limited manufacturing capacity; (vii) the need to improve manufacturing efficiency at PCT; (viii) the limited marketing staff and budget at PCT; (ix) the logistics associated with the distribution of materials produced by PCT; (x) government regulation; (xi) our intellectual property; (xii) cybersecurity; (xiii) the development, approval and commercialization of our products; (xiv) enrolling patients in and completing, clinical trials; (xv) the variability of autologous cell therapy; (xvi) our access to reagents we use in the clinical development of our cell therapy product candidates; (xvii) the validation and establishment of manufacturing controls; (xviii) the failure to obtain regulatory approvals outside the United States; (xix) our failure to realize benefits relating to “fast track” and “orphan drug” designations; (xx) the failure of our clinical trials to demonstrate the safety and efficacy of our product candidates; (xxi) our current lack of sufficient manufacturing capabilities to produce our product candidates at commercial scale; (xxii) our lack of revenue from product sales; (xxiii) the commercial potential and profitability of our products; (xxiv) our failure to realize benefits from collaborations, strategic alliances or licensing arrangements; (xxv) the novelty and expense of the technology used in our cell therapy business; (xxvi) the possibility that our competitors will develop and market more effective, safer or less expensive products than our product candidates; (xxvii) product liability claims and litigation, including exposure from the use of our products; (xxviii) our potential inability to retain or hire key employees; and (xxix) risks related to our capital stock. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.

Past Press Releases

March 15, 2016
Caladrius Biosciences Announces 2015 Fourth Quarter and Full Year Financial Results

March 14, 2016
Caladrius Biosciences Subsidiary PCT, LLC Enters Into Global Collaboration and License Agreement with Hitachi Chemical

February 17, 2016
Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedical

February 10, 2016
Source Capital's 2016 Disruptive Growth & Healthcare Conference

February 9, 2016
18th Annual BIO CEO & Investor Conference

January 28, 2016
Novel Cardiovascular Therapeutics Summit


Contact Us

Anne Marie Fields
Senior Vice President
Phone: +1-212-838-3777


Caladrius Biosciences, Inc.
Eric Powers
Communications and Marketing
Phone: +1-212-584-4173


Rainer Poertner - Chief Analyst    

Please visit our sites and We would appreciate if you could
pass our newsletter on to your friends and colleagues. We always appreciate your feedback and comments.

If you are interested in a research report for your public company, please contact us at

StockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI may have been compensated for the  publication of the information herein and may hold positions in any of the stocks mentioned, which could be considered a conflict of interest. The included information is subject to change without notice. Please visit!legal-ease/lmvw1  for a full text of our Disclaimer, Privacy policy and Terms of Use.
Copyright © 2016 DynamicMarketConcepts, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp